Portal de Periódicos da CAPES

PROSTATE SPECIFIC ANTIGEN VARIATION IN PATIENTS WITHOUT CLINICALLY EVIDENT PROSTATE CANCER

1999; Lippincott Williams & Wilkins; Volume: 162; Issue: 4 Linguagem: Inglês

10.1016/s0022-5347(05)68273-0

1527-3792

M. Luján, Álvaro Páez, Sánchez Sánchez E, ALBERTO HERRERO, Eduardo Martin‐Sanz, Antonio Berenguer,

Urologic and reproductive health conditions

No AccessJournal of UrologyClinical Urology: Original Articles1 Oct 1999PROSTATE SPECIFIC ANTIGEN VARIATION IN PATIENTS WITHOUT CLINICALLY EVIDENT PROSTATE CANCER MARCOS LUJAN, ALVARO PAEZ, ERNESTO SANCHEZ, ALBERTO HERRERO, EDUARDO MARTIN, and ANTONIO BERENGUER MARCOS LUJANMARCOS LUJAN , ALVARO PAEZALVARO PAEZ , ERNESTO SANCHEZERNESTO SANCHEZ , ALBERTO HERREROALBERTO HERRERO , EDUARDO MARTINEDUARDO MARTIN , and ANTONIO BERENGUERANTONIO BERENGUER View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68273-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We address long-term within individual variation of serum prostate specific antigen (PSA) in men without clinical or biopsy evidence of prostate cancer. Materials and Methods: We studied 943 men from a prostate cancer screening program with 2 PSA (PSA1 and PSA2) measurements available. A third PSA (PSA3) was obtained from 571 men. Only participants with no clinical evidence of cancer were included in the study. Within individual PSA variability was calculated based on indexes of percent coefficient of variation, ratio difference and PSA velocity. The relationship among these indexes, interval between measurements and number of PSA samples was assessed. Results: Mean interval was 670.4 days between PSA1 and PSA2, and 801.8 days between PSA2 and PSA3 (p <0.001). Mean coefficient of variation was 18% after 2 and 15.7% after 3 PSA measurements. Mean ratio differences were −0.047 ng./ml. for 2 and 0.033 ng./ml. for 3 samples. Mean PSA velocity was −0.128 ng./ml. per year for 2 and −0.055 ng./ml. per year for 3 samples, with 95% confidence intervals of 0.634 and 0.315, respectively. Variability was higher if only 2 PSA measurements were done (p <0.001). No clear relationship was found between individual variability and interval between measurements. Conclusions: PSA velocity is within normal limits in almost all men (more than 95%) without clinically relevant prostate cancer. PSA individual variability is not fully dependent on the time between measurements when intervals are long, and can be substantially decreased with a third PSA sample. References 1 : Prostate-specific antigen as a marker for prostate cancer: a monoclonal and polyclonal immunoassay compared. Clin. Chem.1987; 33: 1916. Google Scholar 2 : Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol. Clin. N. Amer.1993; 20: 681. Google Scholar 3 : Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. J.A.M.A.1993; 270: 860. Google Scholar 4 : Use of prostate specific antigen density to enhance the predictive value of intermediate levels of prostate specific antigen. J. Urol.1992; 147: 817. Abstract, Google Scholar 5 : Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J.A.M.A.1992; 267: 2215. Google Scholar 6 : Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology1995; 45: 591. Google Scholar 7 : Analysis of variation in prostate-specific antigen values. Urology1993; 42: 390. Google Scholar 8 : Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J. Urol.1996; 155: 1977. Link, Google Scholar 9 : Pitfalls in interpreting prostate specific antigen velocity. J. Urol.1996; 155: 1655. Link, Google Scholar From the Department of Urology, Hospital Universitario de Getafe, Madrid, Spain© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKARAZANASHVILI G and ABRAHAMSSON P (2018) Prostate Specific Antigen and Human Glandular Kallikrein 2 in Early Detection of Prostate CancerJournal of Urology, VOL. 169, NO. 2, (445-457), Online publication date: 1-Feb-2003. Volume 162Issue 4October 1999Page: 1311-1313 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Keywordsprostate-specific antigenprostatic neoplasmstime factorsMetricsAuthor Information MARCOS LUJAN More articles by this author ALVARO PAEZ More articles by this author ERNESTO SANCHEZ More articles by this author ALBERTO HERRERO More articles by this author EDUARDO MARTIN More articles by this author ANTONIO BERENGUER More articles by this author Expand All Advertisement PDF downloadLoading ...